Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SECUKINUMAB Cause Dermatitis exfoliative generalised? 96 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 96 reports of Dermatitis exfoliative generalised have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.1% of all adverse event reports for SECUKINUMAB.

96
Reports of Dermatitis exfoliative generalised with SECUKINUMAB
0.1%
of all SECUKINUMAB reports
5
Deaths
35
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From SECUKINUMAB?

Of the 96 reports, 5 (5.2%) resulted in death, 35 (36.5%) required hospitalization, and 3 (3.1%) were considered life-threatening.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 96 reports have been filed with the FAERS database.

What Other Side Effects Does SECUKINUMAB Cause?

Drug ineffective (27,434) Psoriasis (21,976) Pain (15,244) Arthralgia (13,769) Fatigue (9,406) Psoriatic arthropathy (8,900) Pruritus (8,755) Malaise (8,570) Rash (8,023) Condition aggravated (7,536)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) DUPILUMAB (162) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) VANCOMYCIN (92) AMLODIPINE (91) LENALIDOMIDE (89)

Which SECUKINUMAB Alternatives Have Lower Dermatitis exfoliative generalised Risk?

SECUKINUMAB vs SELADELPAR LYSINE SECUKINUMAB vs SELEGILINE SECUKINUMAB vs SELENIUM SECUKINUMAB vs SELENIUM SULFIDE SECUKINUMAB vs SELEXIPAG

Related Pages

SECUKINUMAB Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised SECUKINUMAB Demographics